Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Aravive	Merrimack Pharmaceuticals	Helix BioPharma	Kazia Therapeutics	Aileron Therapeutics
Symbol	NASDAQ:ARAV	NASDAQ:MACK	OTCMKTS:HBPCF	NASDAQ:KZIA	NASDAQ:ALRN
Price Information
Current Price	$4.65	$6.04	$0.76	$10.01	$1.17
52 Week Range	Buy	N/A	N/A	Buy	Buy
MarketRank™
Overall Score	1.6	1.1	0.5	1.2	1.3
Analysis Score	3.4	0.0	0.0	3.5	3.5
Community Score	2.5	2.9	2.3	1.9	2.6
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	2.5	0.0	0.0	0.0
Earnings & Valuation Score	1.3	0.0	0.0	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	N/A	N/A	Buy	Buy
Consensus Price Target	$25.20	N/A	N/A	$17.00	$3.50
% Upside from Price Target	441.94% upside	N/A	N/A	69.83% upside	199.15% upside
Trade Information
Market Cap	$94.80 million	$81.00 million	$107.80 million	$94.70 million	$105.65 million
Beta	3.2	2.55	0.04	2.76	3.13
Average Volume	213,052	80,856	1,665	145,588	3,252,119
Sales & Book Value
Annual Revenue	$4.75 million	N/A	N/A	$710,000.00	N/A
Price / Sales	19.96	N/A	N/A	133.37	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$4.71 per share	$1.30 per share	$0.02 per share	$1.00 per share	$0.58 per share
Price / Book	0.99	N/A	N/A	10.01	N/A
Profitability
Net Income	$-18,220,000.00	$-17,330,000.00	$-6,680,000.00	$-8,370,000.00	$-29,370,000.00
EPS	($1.57)	N/A	N/A	($1.30)	($1.20)
Trailing P/E Ratio	N/A	0.00	0.00	N/A	N/A
Forward P/E Ratio	N/A	∞	∞	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	N/A	N/A
Return on Equity (ROE)	-47.21%	-14.94%	-325.42%	N/A	-170.37%
Return on Assets (ROA)	-39.11%	-12.96%	-193.46%	N/A	-98.29%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	N/A	0.03%
Current Ratio	11.37%	8.42%	2.22%	2.10%	3.04%
Quick Ratio	11.37%	8.42%	2.22%	2.10%	3.04%
Ownership Information
Institutional Ownership Percentage	40.54%	52.25%	N/A	10.49%	6.67%
Insider Ownership Percentage	30.50%	21.60%	7.60%	1.00%	6.20%
Miscellaneous
Employees	17	27	10	N/A	8
Shares Outstanding	20.39 million	13.41 million	141.13 million	9.46 million	90.30 million
Next Earnings Date	8/2/2021 (Estimated)	5/13/2021 (Estimated)	7/29/2021 (Estimated)	N/A	8/4/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	Aileron Therapeutics (NASDAQ:ALRN) Announces Earnings Results americanbankingnews.com - May 12 at 12:24 PM
	Aileron Therapeutics (NASDAQ:ALRN) Research Coverage Started at HC Wainwright americanbankingnews.com - May 12 at 8:39 AM
	Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update finance.yahoo.com - May 11 at 6:17 PM
	Brokerages Anticipate Aileron Therapeutics, Inc. (NASDAQ:ALRN) Will Post Earnings of -$0.06 Per Share americanbankingnews.com - May 9 at 1:05 AM
	When is Aileron Therapeutics Inc. (ALRN) going to be good investment? marketingsentinel.com - May 5 at 1:45 PM
	Aileron Therapeutics, Inc. (NASDAQ:ALRN)’s Upside Potential Is High stocksregister.com - May 1 at 1:57 PM
	Aileron Therapeutics Inc (ALRN) investing.com - April 25 at 8:10 AM
	Aileron Therapeutics, Inc. (NASDAQ:ALRN) up 73.97% from 52-Week Low; YTD rises 16.35% – Here’s What to Do Now marketingsentinel.com - April 24 at 2:34 PM
	Analysts Anticipate Aileron Therapeutics, Inc. (NASDAQ:ALRN) Will Post Earnings of -$0.06 Per Share americanbankingnews.com - April 21 at 4:24 PM
	Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Update americanbankingnews.com - April 19 at 4:48 AM
	Let’s Jump into the Aileron Therapeutics, Inc. (NASDAQ:ALRN) Stock Forecast marketingsentinel.com - March 29 at 1:45 PM
	William Blair lifts Aileron Therapeutics Inc. [ALRN] price estimate. Who else is bullish? dbtnews.com - March 26 at 6:34 PM
	Aileron Therapeutics, Inc. (NASDAQ:ALRN) – An Analysis Is What You Need stocksregister.com - March 26 at 8:33 AM
	Aileron Therapeutics, Inc. (NASDAQ:ALRN) share price rebounds 80.89% from the lows – but can it keep going? marketingsentinel.com - March 25 at 12:29 PM
	Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides ... apnews.com - March 24 at 7:25 PM
	Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights finance.yahoo.com - March 24 at 7:25 PM
	Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference finance.yahoo.com - March 4 at 12:52 PM
	Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference finance.yahoo.com - March 4 at 12:52 PM
	Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ... apnews.com - March 2 at 7:42 AM
	Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) finance.yahoo.com - March 2 at 7:42 AM
	Aileron Therapeutics, Inc. (ALRN) has great growth outlook for 2021 marketingsentinel.com - February 11 at 12:26 AM
	Aileron Therapeutics Inc. [ALRN] Stock trading around $1.99 per share: What’s Next? dbtnews.com - February 5 at 6:11 PM
	Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners finance.yahoo.com - January 11 at 9:33 AM
	Aileron Announces $35.9 Mln Registered Direct Offering; Stock Down nasdaq.com - January 6 at 3:17 PM
	Aileron Therapeutics Announces $35.9 Million Registered Direct Offering finance.yahoo.com - January 6 at 10:14 AM

Date	Company	Brokerage	Action
4/27/2021	Aravive	HC Wainwright	Reiterated Rating
3/15/2021	Aravive	BTIG Research	Initiated Coverage
11/9/2020	Aravive	Piper Sandler	Lower Price Target
9/18/2020	Aravive	William Blair	Initiated Coverage
8/14/2020	Aravive	Wedbush	Reiterated Rating
8/13/2020	Aravive	Cantor Fitzgerald	Reiterated Rating
12/20/2019	Aravive	Piper Jaffray Companies	Reiterated Rating
12/2/2019	Aravive	Robert W. Baird	Upgrade
11/7/2018	Merrimack Pharmaceuticals	Cowen	Reiterated Rating
6/25/2018	Merrimack Pharmaceuticals	JPMorgan Chase & Co.	Downgrade
11/16/2020	Aileron Therapeutics	Canaccord Genuity	Reiterated Rating

(Data available from 5/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources